| Literature DB >> 34571020 |
Alfredo Tagarro1, Francisco José Sanz-Santaeufemia2, Carlos Grasa3, Elena Cobos4, Julia Yebra5, Jose Antonio Alonso-Cadenas6, Fernando Baquero-Artigao3, Juan Miguel Mesa-Guzmán5, Beatriz Pérez-Seoane5, Cristina Calvo3, María Luisa Herreros5, Cristina Epalza7, Susana Melendo8, Sara Dominguez-Rodriguez4, Paula Vidal9, Mónica Pacheco5, Alvaro Ballesteros4, María Bernardino10, Sara Villanueva-Medina11, Paula Rodríguez-Molino3, Sandra Miragaya Castro6, Jacques Rivière8, Rosa Garcés9, Begoña Santiago12, Victoria Fumadó13, María Urretavizcaya-Martínez14, María Luz García-García15, María Penín16, Fernando Cava17, Elena Sáez17, María Isabel Iglesias-Bouzas18, Blanca Herrero19, Teresa de Jesús Reinoso20, Cinta Moraleda7.
Abstract
OBJECTIVES: To determine the time to reverse transcription-polymerase chain reaction (RT-PCR) negativity after the first positive RT-PCR test, factors associated with longer time to RT-PCR negativity, proportion of children seroconverting after proven severe acute respiratory syndrome coronavirus 2 infection, and factors associated with the lack of seroconversion. STUDYEntities:
Keywords: COVID-19; RT-PCR; SARS-CoV-2; children; dynamics; seroconversion; serology
Mesh:
Year: 2021 PMID: 34571020 PMCID: PMC8463102 DOI: 10.1016/j.jpeds.2021.09.029
Source DB: PubMed Journal: J Pediatr ISSN: 0022-3476 Impact factor: 4.406
Figure 1A, Ct over time. The line represents an inference of the trajectory of Cts until negativity. Negative values are presented as a Ct of 45. Negative values beyond 60 days are not presented. B, Box-and-whiskers distributions of Ct across weeks. Most of the samples had a high Ct value. At diagnosis, the median Ct was 38.5 (IQR, 35.5-40.0).
Figure 2Probability of RT-PCR negativity by A, severity, B, immunosuppressive medication or C, phenotype. PICU, pediatric intensive care unit; URTI, upper respiratory tract infection.
Figure 3Flowchart of patients with serologic follow-up. Overall, at least 22/93 (23.6%) children with a recent RT-PCR positive test and available serum specimens did not develop detectable IgG SARS-CoV-2 antibodies. N/A, not applicable.
Figure 4Probability of RT-PCR test negativity in all 324 participants.
Characteristics of initially IgG-negative patients who had follow-up IgG serology
| Characteristics | Total | Not seroconverted | Seroconverted | OR | |
|---|---|---|---|---|---|
| (n = 49) | (n = 22) | (n = 27) | [95% CI] | ||
| Sex | .827 | ||||
| Male | 27 (55.1%) | 13 (59.1%) | 14 (51.9%) | Ref. 1.00 | |
| Female | 22 (44.9%) | 9 (40.9%) | 13 (48.1%) | 1.33 [0.42-4.30] | |
| Age (months) | NA = 1 (2.0%) | NA = 0 (0.0%) | NA = 1 (3.7%) | ||
| Median [IQR] | 38.3 [1.83-130] | 93.7 [13.9-163] | 10.1 [1.23-78.4] | 0.99 [0.98-1.00] | |
| Fever days | NA = 9 (18.4%) | NA = 6 (27.3%) | NA = 3 (11.1%) | ||
| Median [IQR] | 2.50 [0.00-4.00] | 0.00 [0.00-3.00] | 3.00 [1.00-4.00] | 1.56 [1.04-2.35] | |
| Immunosuppressive medication | 1.000 | ||||
| No | 45 (91.8%) | 20 (90.9%) | 25 (92.6%) | Ref. 1.00 | |
| Yes | 4 (8.16%) | 2 (9.09%) | 2 (7.41%) | 0.80 [0.08-8.29] | |
| Severity | |||||
| Not hospitalized | 17 (34.7%) | 12 (54.5%) | 5 (18.5%) | Ref. 1.00 | |
| Hospitalized (PICU and normal wards) | 32 (65.3%) | 10 (45.5%) | 22 (81.5%) | 5.01 [1.43-20.1] | |
| Cycle threshold of RT-PCR at diagnosis | NA = 31 (63.3%) | NA = 10 (45.5%) | NA = 21 (77.8%) | .589 | |
| Median [IQR] | 38.5 [35.5-40.0] | 38.0 [36.5-40.0] | 40.0 [11.5-40.0] | 0.96 [0.90-1.03] | |
| PICU or high-flow oxygen necessity | NA = 1 | 1.000 | |||
| No | 44 (91.7%) | 20 (90.9%) | 24 (92.3%) | Ref. 1.00 | |
| Yes | 4 (8.33%) | 2 (9.09%) | 2 (7.69%) | 0.84 [0.08-8.64] | |
| Time between first (−) and second serology (+) | - | ||||
| Median [IQR] | - | - | 28.0 [25.5-34.5] | - | |
| RT-PCR negativity | |||||
| No | 6 (13.0%) | 0 (0.00%) | 6 (25.0%) | ||
| Yes | 40 (87.0%) | 22 (100%) | 18 (75.0%) | - | |
| Clinical phenotype | .744 | ||||
| Asymptomatic | 5 (10.2%) | 3 (13.6%) | 2 (7.41%) | Ref. 1.00 | |
| URTI/flu-like/fever without source | 30 (61.2%) | 12 (54.5%) | 18 (66.7%) | 2.15 [0.29-20.8] | |
| Pneumonia/bronchitis | 7 (14.3%) | 4 (18.2%) | 3 (11.1%) | 1.11 [0.09-14.8] | |
| Gastrointestinal | 7 (14.3%) | 3 (13.6%) | 4 (14.8%) | 1.86 [0.17;25.4] | |
PICU, pediatric intensive care unit; NA, not available; PICU, pediatric intensive care unit; URTI, upper respiratory tract infection. Values in bold are statistically significant (P-value <.05).